GlassScriptPhysician profile
Tara Fischer
NPI 1225669880
$10,711.45
in general payments reported to CMS, 2019-2025
25 companies · $3,152 in 2025
The $3,152 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,828 · 2022: $2,264 · 2023: $1,799 · 2024: $1,668 · 2025: $3,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,616 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,615.53 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,502.59 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,446.52 | 2021-2025 | |
| Alkermes, INC. | $1,289.91 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,193.32 | 2021-2025 | Caplyta |
| Lundbeck LLC | $979.77 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $911.09 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $631.03 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $627.87 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $583.47 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $458.86 | 2021-2022 | |
| Axsome Therapeutics, INC. | $306.96 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $143.18 | 2023-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $131.54 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $115.98 | 2025 | Cobenfy |
| Bausch Health US, LLC | $57.12 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $56.19 | 2023-2024 | Perseris |
| Corium, LLC | $54.89 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $44.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.83 | 2025 | Invega Sustenna, Spravato |
| Orexo US, INC. | $33.50 | 2021 | |
| Luye Pharma (USA) LTD. | $23.12 | 2025 | Erzofri Extended-Release |
| Collegium Pharmaceutical, INC. | $23.08 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $20.73 | 2022 | |
| Noven Therapeutics, LLC | $19.20 | 2024 | Xelstrym, Secuado |
| Eisai INC. | $15.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.